Showing results (621-630 of 736) with videos related to

Sort By:
Pageof 74
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Haematologica|December 4, 2025
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemiaKaran Chohan, Jonas Paludo, Surendra Dasari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal GammopathiesPatrizia Mondello, Jonas Paludo, Joseph P Novak, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 13, 2015
Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph ConsortiumEleanor Kane, Christine F Skibola, Paige M Bracci, et al.
Mayo Clinic Proceedings|October 3, 2008
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiativeMorie A Gertz, Stephen M Ansell, David Dingli, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Blood Cancer Journal|January 29, 2022
Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?Rebecca L King, Alia Gupta, Paul J Kurtin, et al.
Blood Cancer Journal|August 29, 2015
Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphomaA J Novak, Y W Asmann, M J Maurer, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
Blood Advances|August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 studyStephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Pageof 74